<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01351753</url>
  </required_header>
  <id_info>
    <org_study_id>201012738</org_study_id>
    <nct_id>NCT01351753</nct_id>
  </id_info>
  <brief_title>Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity</brief_title>
  <acronym>REVIVE</acronym>
  <official_title>Does Reversal of Visceral Obesity by Drug Therapy Improve Vascular Function?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is common (&gt;30% of US adults), contributes to substantial morbidity and mortality,
      but is difficult to treat. Partly this is due to the transient, arduous and modest nature of
      lifestyle interventions. Partly it is due to the limited efficacy and safety problems of
      existing pharmacotherapy. Only one drug, orlistat, is approved for long-term use in obesity;
      but its effects on weight are relatively small. There are drugs that have been approved for
      other diseases but which also reduce weight. One promising approach to treating obesity is
      combination therapy with orlistat and one or more of these other agents. The investigators
      propose an innovative approach to developing new therapies for obesity coupling the use of
      combination therapy with rigorous assessment of cardiovascular safety. Vascular function is a
      quantitative surrogate clinical endpoint that has been strongly and independently linked to
      future cardiovascular events.

      Our hypothesis is that combination pharmacotherapy will reduce weight and improve vascular
      function in obese human subjects. The co-primary endpoints will be weight and vascular
      function.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Change of staff
  </why_stopped>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight (change from baseline)</measure>
    <time_frame>12 months</time_frame>
    <description>Weight obtained in the fasting state on a gowned subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brachial artery flow mediated dilatation (change from baseline)</measure>
    <time_frame>12 months</time_frame>
    <description>Conduit artery flow mediated dilatation (FMD) assessed using ultrasound-Doppler.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with mild, moderate and serious adverse events.</measure>
    <time_frame>12 months</time_frame>
    <description>Gastrointestinal, central nervous system, psychiatric, hepatic, renal, musculoskeletal and other adverse effects will be regularly assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic and diastolic systemic arterial pressure (change from baseline)</measure>
    <time_frame>12 months</time_frame>
    <description>Automated sphygmomanometry while sitting and 24-hour ambulatory BP monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting lipids, glucose and other biomarkers of obesity risk (change from baseline)</measure>
    <time_frame>12 months</time_frame>
    <description>Fasting total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol, hsCRP, glucose, HBA1c, ALT, creatinine, eGFR, microalbuminuria, EKG voltage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood, anxiety, quality of life and cognitive function (change from baseline)</measure>
    <time_frame>12 months</time_frame>
    <description>Mood assessed using Beck Depression Inventory. Anxiety assessed using Beck Anxiety Inventory. Quality of life assessed using SF-36 and IWQOL surveys. Cognition assessed using Trail Making A &amp; B, Controlled Oral Word Association, and Letter-Number Sequencing Tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat distribution (change from baseline)</measure>
    <time_frame>12 months</time_frame>
    <description>Body fat distribution measured using anthropometry (waist, neck and hip circumferences), as well as air displacement plethysmography, electrical bioimpedance, and DEXA in subsets of subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity (PWV) and aortic augmentation pressure (change from baseline)</measure>
    <time_frame>12 months</time_frame>
    <description>Carotid-femoral pulse wave velocity and estimated aortic augmentation pressure measured using pulse tonometry (Sphygmocor).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral arteriolar tonometry</measure>
    <time_frame>12 months</time_frame>
    <description>Reactive hyperemia in finger tip measured using EndoPAT.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Obesity</condition>
  <condition>Metabolic Syndrome X</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin + Orlistat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin + Topiramate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Topiramate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin + Topiramate + Orlistat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_label>Metformin + Orlistat</arm_group_label>
    <arm_group_label>Metformin + Topiramate</arm_group_label>
    <arm_group_label>Metformin + Topiramate + Orlistat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orlistat</intervention_name>
    <arm_group_label>Metformin + Orlistat</arm_group_label>
    <arm_group_label>Metformin + Topiramate + Orlistat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
    <arm_group_label>Metformin + Topiramate</arm_group_label>
    <arm_group_label>Topiramate</arm_group_label>
    <arm_group_label>Metformin + Topiramate + Orlistat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pills and capsules for metformin, orlistat and topiramate</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 40 to 75 years

          -  Male or postmenopausal female

          -  BMI â‰¥ 30 kg/m2

          -  One or more major cardiovascular (CV) risk factors (hypertension, dyslipidemia,
             impaired glucose tolerance OR metabolic syndrome)

        Exclusion Criteria:

          -  Congestive heart failure

          -  Renal impairment

          -  History of bariatric surgery (i.e. lap-band, Roux-en-Y or biliopancreatic diversion)

          -  Type I diabetes mellitus

          -  Weight loss &gt; 10% in the past 6 months

          -  Recurrent nephrolithiasis

          -  Current treatment for seizure disorder

          -  Hepatic cirrhosis

          -  Current use of study medications

          -  Current use of oral estrogen

          -  History of smoking cessation in the past three months

          -  Current cholestasis or malabsorption syndrome

          -  Planned use of any herbal or over-the-counter supplements for weight loss

          -  History of allergic reactions to metformin, topiramate, orlistat or any of ingredients

          -  Medical conditions requiring continuous use of phosphodiesterase inhibitors and/or the
             inability to withhold phosphodiesterase inhibitors for 48 hours

          -  Participation in another clinical drug study within four weeks prior to this
             investigation.

          -  Participation in any other weight loss or rigorous exercise program.

          -  Any disease or condition that in the opinion of the investigator may interfere with
             completion of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary L Pierce, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://goo.gl/IHNtm</url>
    <description>Recruitment website</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2011</study_first_submitted>
  <study_first_submitted_qc>May 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2011</study_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Gary L. Pierce</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Metabolic Syndrome X</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Impaired glucose tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Orlistat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

